Featured

AbbVie Seeks FDA Approval for Venetoclax and Acalabrutinib Combination in Untreated CLL

AbbVie submitted a supplemental New Drug Application (sNDA) to the FDA for a fixed-duration, all-oral combination of VENCLEXTA (venetoclax) and acalab...

Home/KnolSights/Regulatory Approvals/AbbVie Seeks FDA Approval for Venetoclax and Acalabrutinib Combination in Untreated CLL